The $50 Medicare GLP-1 Price Excludes Three Diagnoses
Author
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
If you have type 2 diabetes, moderate to severe sleep apnea, or fatty liver disease with scarring, you are not eligible for the Medicare GLP-1 Bridge and its $50 monthly copay. Medicare routes you back to your Part D plan instead, where the same medication can run $200 to $600 a month in copay costs. Cash pay is sometimes cheaper than that, but it carries a catch of its own.
Who This Helps
This is for you if you're on Medicare, you were turned away from the $50 program, and your plan's copay is worse than you expected. If your claim was rejected at the counter, start with our walkthrough of what a rejected Bridge claim actually means, because most first fills are rejected on purpose.
Three diagnoses send you back to your Part D plan
The Bridge is a demonstration running July 1, 2026 through December 31, 2027, with a $50 monthly copay for Wegovy in two formulations (including the Wegovy Pill), Zepbound in the KwikPen only, and Foundayo (CMS, Medicare.gov). It is built for people who cannot get these medications covered any other way.
That design is also the exclusion. CMS states it directly: "Type 2 diabetes, moderate to severe obstructive sleep apnea, and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) indications are eligible for Part D coverage. Beneficiaries with these diagnoses are eligible to receive GLP-1s through their Part D plan and therefore are ineligible to receive them through the Medicare GLP-1 Bridge, even if they otherwise meet the Medicare GLP-1 Bridge clinical criteria" (CMS).
Being prescribed one to reduce only cardiovascular risk routes you the same way.
Being covered and being able to afford it aren't the same thing. A primary care physician told NPR that "'coverage' doesn't always mean 'affordable,'" describing patients who reach the counter and find copays of $200 to $600 a month (NPR). A KFF analysis reported there estimates 3.8 million people qualify for the Bridge, and more than 600,000 signed up in its first two months (Newsweek).
The $50 does not count toward your $2,100 cap, and neither does cash pay
Medicare's 2026 out-of-pocket limit for Part D drugs is $2,100, and once your covered spending reaches it you pay nothing more for covered drugs that year (Medicare.gov). Anything paid outside the Part D benefit doesn't move you toward it, and that cuts both ways.
- The Bridge $50: does not count. Medicare's own fact sheet says "this $50 payment doesn't count toward your Medicare drug plan deductible or yearly out-of-pocket limit" (Medicare.gov).
- Cash pay: does not count either. Novo Nordisk's own terms say the self-pay price "operates outside of any third-party insurance" and that "the money spent and discounts on your prescription will not count toward your deductible or out-of-pocket requirements" (NovoCare).
- A Part D copay: does count. Every dollar moves you toward the $2,100, after which your covered drugs cost you nothing.
Bridge medications are also excluded from the Medicare Prescription Payment Plan, which lets you spread out-of-pocket costs across the year rather than paying at the counter (Medicare.gov). It applies only to covered Part D drugs (CMS).
Cash pay can beat a Part D copay, and the answer depends on your other drugs
Self-pay prices are shared on GLP Winner up front. As of September 2026, Novo Nordisk lists the Wegovy pen at $349 a month for standard doses after an introductory period, and the pill from $149 to $299 by dose (NovoCare). Against a Part D copay at the high end of that $200 to $600 range, cash pay wins on the monthly number.
- If a GLP-1 is your only expensive medication: cash pay may cost less across the year, because you were unlikely to be helped much by a cap you would reach late or not at all.
- If you take several costly medications: paying through Part D is usually better, because the GLP-1 pushes you to the $2,100 ceiling faster and everything else that year becomes free.
Nobody can run that comparison from a webpage, because it turns on your plan's tier for the drug, your other prescriptions, and where you sit in the year. A plan representative can, and so can a free counselor at your State Health Insurance Assistance Program (SHIP). Medicare's number is 1-800-633-4227. Ask two things: what tier is this drug on my plan, and what's my projected annual out-of-pocket through the plan. If you hit your out of pocket maximum before December, it may be worth paying the higher copay instead of going with a cash-pay choice.
If your plan says no and you don’t qualify for the Bridge, there is a formulary exception before there is an appeal
Medicare can't cover a drug used only for weight loss. The statute behind that excludes "agents when used for anorexia, weight loss, or weight gain" (42 U.S.C. 1396r-8). Part D coverage of your GLP-1 hangs on a different qualifying diagnosis, which is why the three conditions above open a door the Bridge closes.
When a plan refuses to pay for a medication it normally covers, like a GLP-1, the first move is a formulary exception rather than an appeal. Your prescriber submits a supporting statement explaining that covered alternatives "would not be as effective or would have adverse effects," and the plan must decide within 24 hours for an expedited request or 72 for a standard one (CMS). Only then does the Part D five-level appeals process open (CMS), starting with a redetermination you have 65 days to file (CMS redetermination guidance).
There is no appeals process inside the Bridge itself. If a Bridge authorization is denied on incorrect information, your prescriber resubmits the form, and your Part D appeal rights stay separate. Plan changes happen during Medicare open enrollment, October 15 to December 7 (Medicare.gov), when the Plan Finder can compare plans against your actual drug list. That date is coming up, so be on the lookout for formulary changes for next year.
A custom dose is a different question from a cheaper price
Compounded medications come up here, and they answer a narrower question than people expect. Part D doesn't pay for them, and cash spent on one won't count toward your cap, so this isn't a route around the pricing problem.
Where a compounded GLP-1 product genuinely helps is dosing. A prescriber may find a patient needs a strength that isn't commercially made, usually a smaller step between two manufactured doses for someone who can't tolerate the standard jump. That's a documented clinical judgment made with a licensed pharmacy, and a legitimate pathway rather than a workaround. Our explainer on how 503A and 503B pharmacies differ covers what to ask.
Final Takeaway
Being told you don't qualify for the $50 price because you're sick enough to have another diagnosis is a frustrating thing to hear. Medicare's position is that another door is already open to you. Whether that door is affordable is a separate question, and one you can actually get answered. Compare the monthly cash price against your plan's copay, then compare both against what you'll spend on everything else this year. Call your plan or a free counselor first, because the right answer changes with your prescription list. Whichever way you go, it isn't permanent.
If you enjoy posts like these, you can subscribe to receive newsletter updates.
Frequently Asked Questions
Why was I denied the $50 Medicare GLP-1 price if I have diabetes?
Because Medicare considers you already covered. CMS excludes people with type 2 diabetes, moderate to severe obstructive sleep apnea, or MASH from the Bridge, on the basis that Part D already covers GLP-1s for those diagnoses. You keep coverage, but you pay your plan's copay rather than $50.
Does paying cash for a GLP-1 count toward my Medicare out-of-pocket limit?
No. Cash purchases through a manufacturer self-pay program sit outside the Part D benefit, so they don't count toward your deductible or the $2,100 annual out-of-pocket limit for 2026. The Bridge $50 copay doesn't count either. Only spending processed through your plan moves you toward the cap.
Can someone on Medicare use manufacturer self-pay pricing?
Yes, provided they pay outside their insurance. Novo Nordisk's terms state that patients enrolled in government-funded prescription programs are able to pay the self-pay price. That is different from a commercial copay card, which government beneficiaries generally cannot use.
Sources
Find a provider in your state
Answer a few questions and see live pricing from the providers that ship where you live.
Keep Reading
Do you need a rejected claim before the Medicare GLP-1 Bridge prior authorization? What CMS actually says, and how the process really works.
A rejected Medicare GLP-1 Bridge claim is usually a paperwork step, not a denial. See the four reasons and what to ask your pharmacy.
The Medicare GLP-1 Bridge starts July 1, 2026. See who qualifies, which drugs cost $50, and how the prior authorization works step by step.
Categories
Written by
Lauren PescarusLauren Pescarus is a team member with GLP Winner where she works on marketing, content creation, and operations. She has over 10 years experience in the content creation space, including in the GLP-1 space where she works to stay on top of access news, research updates, and lifestyle tips guided by science.